SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1S324.
  • Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M et al. (2011). Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic activity. Proc Natl Acad Sci U S A 108: 1848818493.
  • AlvarezCurto E, Prihandoko R, Tautermann CS, Zwier JM, Pediani JD, Lohse MJ et al. (2011). Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol 80: 10331046.
  • Ariens EJ (1954). Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther 99: 3249.
  • Baneres J-L, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaret J (2005). Molecular characterization of a purified 5-HT4 receptor. J Biol Chem 280: 2025320260.
  • Berg KA, Maayani S, Goldfarb J, Scaramelli C, Leff P, Clarke WP (1998). Effect pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94104.
  • Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008). A conservative, single-amino acid substitution in the second cytoplasmic domain of the human serotonin2C receptor alters both lignd-dependent and –independent receptor signaling. J Pharmacol Exp Ther 324: 10841092.
  • Bhattacharya S, Hall SE, Li H, Vaidehi N (2008). Ligand-stabilized conformational states of human β2 adrenergic receptor: insight into G-protein-coupled receptor activation. Biophys J 94: 20172042.
  • Black JW, Leff P (1983). Operational models of pharmacological agonist. Proc R Soc Lond [Biol] 220: 141162.
  • Black JW, Leff P, Shankley NP (1985). An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84: 561571.
  • Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC (2011). Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II Type I receptor, in healthy and heart failure canine: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4: 770778.
  • Bosshard HR (2001). Molecular recognition by induced fit: how fit is the concept? News Physiol Sci 16: 171173.
  • Burgen ASV (1981). Confomrational changes and drug action. Fed Proc 40: 27232728.
  • Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, Bottrill A et al. (2011). Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling barcode. J Biol Chem 286: 1150611518.
  • Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme C et al. (2000). Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57: 125134.
  • Chidiac P, Nouet P, Bouvier M (1996). Agonist-induced modulation of inverse agonist efficacy at the beta-2 adrenergic receptor. Mol Pharmacol 50: 662666.
  • Christmanson L, Westermark P, Betsholtz C (1994). Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem Biophys Res Commun 205: 12261235.
  • Clark AJ (1937). General Pharmacology: in: ‘Heffner's Handbuch Der Experimentellen Pharmacologie Ergänzungsband, Band 4. Springer-Verlag: Berlin.
  • Conklin BR, Hsiao EC, Claeyson S, Dumuis A, Srinivasan S, Forsayeth JR et al. (2008). Engineering GPCR signaling pathways with RASSLs. Nat Methods 5: 673678.
  • Costa T, Herz A (1989). Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 86: 73217325.
  • Cottingham C, Chen Y, Wang Q (2011). The antidepressant desipramine is an arrestin-biased ligand at the a2-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J Biol Chem 286: 3606336075.
  • Dacres H, Wang J, Leitch V, Horne I, Anderson AR, Trowell SC (2011). Greatly enhanced detection of a volatile ligand at femtomolar levels using bioluminescence resonance energy transfer (BRET). Biosens Bioelectron 29: 119124.
  • DeLean A, Stadel JM, Lefkowitz RJ (1980). A ternary complex model explains the agonist-specific binding properties of adenylate cyclase coupled β-adrenergic receptor. J Biol Chem 255: 71087117.
  • DeWire S, Violin JD (2011). Biased ligands for better cardiovascular drugs. Dissecting G-protein-coupled receptor pharmacology. Circ Res 109: 205216.
  • Doll C, Konietzko F, Pöll F, Köch T, Holt V, Schultz S (2011). Agonist-selective patterns of m-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164: 298307.
  • Dong S, Rogan SC, Roth BL (2010). Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc 5: 561573.
  • Ehlert FJ (1988). Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33: 187194.
  • Ehlert FJ (2005). Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315: 740754.
  • Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ (2010). Ligand-directed signaling at β-adrenoceptors. Br J Pharmacol 159: 10221038.
  • Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A et al. (2011). Quantification of Functional Selectivity at the Human α1A-Adrenoceptor. Mol Pharmacol 79: 298307.
  • Fang Y (2010a). Live cell optical sensing for high throughput applications. Adv Biochem Eng Biotechnol 118: 153164.
  • Fang Y (2010b). Label-free receptor assays. Drug Disc Today 7: e5e11.
  • Fathy DB, Lee L, Mathis SA, Leeb-Lundberg LMF (1999). Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. J Biol Chem 274: 2960329606.
  • Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT et al. (2005). Bone response to intermittent parathyroid hormone is altered in mice bull for (beta) arrestin 2. Endocrinol 146: 18541862.
  • Figueroa KW, Griffin MT, Ehlert FJ (2009). Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328: 331342.
  • Fisher A, Heldman E, Gurwitz D, Haring R, Barak D, Meshulam H et al. (1993). Selective signaling via unique M1 muscarinic agonists. Ann N Y Acad Sci 695: 300303.
  • Fraunfelder H, Parak F, Young RD (1988). Conformational substrates in proteins. Annu Rev Biophys Biophys Chem 17: 451479.
  • Fraunfelder H, Sligar SG, andWolynes PG (1991). The energy landscapes and motions of proteins. Science 254: 15981603.
  • Freire E (1998). Statistical thermodynamic linkage between conformational and binding equilibria. Adv Protein Chem 51: 255279.
  • Furchgott RF (1966). The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper NJ , Simmonds AB (eds). Advances in Drug Research., Vol. 3. Academic Press: New York, pp. 2155.
  • Galandrin S, Bouvier M (2006). Distinct signaling profiles of b1 and b2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 15751158.
  • Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M (2008). Conformational rearrangements and signaling cascades invovled in ligand-based mitogen-activated protein kinase singaling through the β1-adrenergic recepor. Mol Pharmacol 74: 162172.
  • Georgieva T, Devanathan S, Stropova D, Park PK, Salamon Z, Tollin G et al. (2008). Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 581: 1929.
  • Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S et al. (2006). Distinct β-Arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281: 1085610864.
  • Gesty-Palmer D, Flanner P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ et al. (2009). A b-arrestin-biased agonist of the parathyroid hormone receptor (PTHR1) promotes bone formation independent of G protein activation. Sci Transl Med 1: 1ra1.
  • Gether U, Lin S, Kobilka BK (1995). Fluorescent labeling of purified β2-adrenergic receptor: evidence for ligand specific conformational changes. J Biol Chem 270: 2826828275.
  • Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR et al. (2001). Functionally different agonists produce distinct conformations in G-protein coupling domains of the β2-adrenergic receptor. J Biol Chem 276: 2443324436.
  • Granier S, Kim T, Shafer AM, Ratnala VR, Fung JJ, Zare RN et al. (2007). Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 282: 1389513905.
  • Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56: 441451.
  • Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE et al. (2007). An opioid agonist that does not induce mu opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71: 549557.
  • Gudermann T, Kalbrenner F, Schultz G (1996). Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 36: 429459.
  • Guo D, Mulder-Krieger T, IJzerman AP, Heitman LH (2012). Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 166: 18461859.
  • Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A (1994). Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. Eur J Pharmacol 267: 2131.
  • Heldman E, Barg J, Fisher A, Levy R, Pittel Z, Zimlichman R et al. (1996). Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. Eur J Pharmacol 297: 283291.
  • Hermans E (2003). Biochemical and pharmacological control of the multiplicity of coupling at G-protein coupled receptors. Pharmacol Ther 99: 2544.
  • Hilser J, Freire E (1997). Predicting the equilibrium protein folding pathway: structure-based analysis of staphylococcal nuclease. Prot Struct Func Genet 27: 171183.
  • Hilser J, Dowdy D, Oas TG, Freire E (1998). The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc Natl Acad Sci U S A 95: 99039908.
  • Hilser VJ, Garcia-Moreno EB, Oas TG, Kapp G, Whitten ST (2006). A statistical thermodynamic model of protein ensembles. Chem Rev 106: 15451558.
  • Hruby VJ, Tollin G (2007). Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities. Curr Opin Pharmacol 7: 507514.
  • Kelly E (2011). The subtleties of μ-opioid receptor phosphorylation. Br J Pharmacol 164: 294297.
  • Kenakin T (1996). Receptor conformational induction versus selection: all part of the same energy landscape.[Editorial]. Trends Pharmacol Sci 17: 190191.
  • Kenakin TP (1984). The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors. Br J Pharmacol 81: 131143.
  • Kenakin TP (1995a). Agonist-receptor efficacy II: Agonist-trafficking of receptor signals. Trends Pharmacol Sci 16: 232238.
  • Kenakin TP (1995b). Pharmacological proteus trends. Pharmacol Sci 16: 256258.
  • Kenakin TP (1997). Agonist-specific receptor conformations. Trends Pharmacol Sci 18: 416417.
  • Kenakin TP (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598611.
  • Kenakin TP (2002a). Efficacy at G Protein coupled receptors. Annu Rev Pharmacol Toxicol 42: 349379.
  • Kenakin TP (2002b). Efficacy at G Protein coupled receptors. Nat Rev Drug Discov 1: 103109.
  • Kenakin TP (2005). New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Rev Drug Disc 4: 919927.
  • Kenakin TP (2006). Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Disc 1: 635652.
  • Kenakin TP (2007). Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72: 13931401.
  • Kenakin TP (2008). Pharmacological onomastics: what's in a name? Br J Pharmacol 153: 432438.
  • Kenakin TP (2009a). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Rev Drug Disc 8: 617626.
  • Kenakin TP (2009b). 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30: 460469.
  • Kenakin TP (2010). Perspectives in pharmacology: functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336: 296302.
  • Kenakin TP, Miller LJ (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265304.
  • Kenakin TP, Onaran O (2002). The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23: 275280.
  • Kenakin TP, Ambrose JR, Irving PE (1991). The relative efficiency of β-adrenoceptor coupling to myocardial inotropy and diastolic relaxation: organ selective treatment for diastolic dysfunction. J Pharmacol Exp Ther 257: 11891197.
  • Kenakin TP, Morgan P, Lutz M, Weiss J (2000). The evolution of drug-receptor models: the cubic ternary complex model for G-protein coupled receptors. In: Kenakin TP , Angus JA (eds). Handbook of Experimental Pharmacology, Vol 148, General Pharmacology: The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems'. Springer-Verlag: Berlin, pp. 147166.
  • Kenakin TP, Watson C, Muniz-Medina V, Christopoulos A, Novick S (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3: 193203.
  • Kew JNC, Trube G, Kemp JA (1996). A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons. J Physiol 497.3: 761772.
  • Kobilka BK, Gether U (2002). Use of fluorescence spectroscopy to study conformational changes in the beta-adrenoceptor. Methods Enzymol 343: 170182.
  • Kocan M, Pfleger KDG (2009). Detection of GPCR/β-arrestin interactions in live cells using bioluminescence resonance energy transfer technology. In: Leifert WR (ed.). Human Press, New York, pp. 305317. ed. G Protein-Coupled Receptors in Drug Discovery., Vol. 552.
  • Kocan M, Pfleger KDG (2011). Study of GPCR-protein interactions by BRET. In: Willars GB , Challiss J (eds). Meth. Mol. Biol., Receptor Signal Transduction Protocols, 3rd edn., Vol. 746. Human Press, Totowa, NJ, pp. 357371.
  • Kocan M, Dalrymple MB, Seeber RM, Feldman BJ, Pfleger KDG (2011). Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and arrestins. Frontiers Endocrinol 1: 19.
  • Koole C, Wootten D, Simms J, Valant C, Sridhaar R, Woodman OL et al. (2010). Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456465.
  • Koshland DE Jr (1958). Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci U S A 44: 98104.
  • Kukkonen JP (2004). Regulation of receptor-coupling to (multiple) G proteins: a challenge for basic research and drug discovery. Receptors Channels 10: 167183.
  • Lau E, Lytle C, Straus DS, DeFea KA (2010). Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in intestinal epithelium. Am J Physiol Cell Physiol 300: C113C123.
  • Lau EK, Trester-Zedlitz M, Trinidad JC, Kotowski SJ, Krutchinsky AN, Burlingame AL et al. (2011). Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal 4: 111. Available at: http://www.ScienceSignaling.org (accessed 16 November 2012).
  • Lawler CO, Watts VJ, Booth RG, Southerland SB, Mailman RB (1994). Discrete functional selectivity of drugs: OPC-14597, a selective antagonist for post-synaptic dopamine D2 receptors. Abstr. Soc Neurosci 20: 525.
  • Lawler CP, Prioleua C, Lewis MM, Mak C, Jiang D, Schetz JA et al. (1999). Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes. Neuropsychopharmacology 20: 612627.
  • Leach K, Sexton PM, Christopoulos A (2007). Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382389.
  • Leeb-Lundberg LMF, Kang DS, Lamb ME, Fathy DB (2001). The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. J Biol Chem 276: 87858792.
  • Liu JG, Ruckle MB, Prather PL (2001). Constitutively active m-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4, Gly-ol5]enkephalin. J Biol Chem 276: 3777937786.
  • Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K (2012). Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335: 11061110.
  • Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Vilardaga JP, Bunemann M (2008). Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol 153: S125S132.
  • Ma B, Shatsky M, Wolfson HJ, Nussinov R (2002). Multiple diverse ligands binding at a single protein site: a matter of pre-existing conformations. Protein Sci 11: 184197.
  • Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y et al. (2004). Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78: 86548662.
  • Mailman RB (2007). GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28: 390396.
  • Mailman RB, Lawler CP, Lewis MM, Blake B (1998). Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step. In: Jenner P , Demirdamar R (eds). Dopamine Receptor Subtypes: From Basic Science to Clinical Application. IOS Press: Fairfox, CA, pp. 112119.
  • Mary S, Damian M, Louet M, Floquet N, Fehrentz J-A, Marie J et al. (2012). Ligands and signaling proteins govern the conformational landscape explored by G protein-coupled receptor. Proc Natl Acad Sci U S A 109: 83048309. pnas1119881109.
  • Maudsley S, Martin B, Luttrell LM (2005). The origins of diversity and specificity in G protein-coupled recetor signaling. J Pharmacol Exp Ther 314: 485494.
  • Metra M, Cas LD, di Lenarda A, Poole-Wilson P (2004). Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 9: 123130.
  • Mottola DM, Cook LL, Jones SR, Booth RG, Nichols DE, Mailman RB (1991). Dihydrexidine, a selective dopamine receptor agonist that may discriminate postsynaptic D2 receptors. Abstr. Soc Neurosci 17: 818.
  • Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR et al. (2002). Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D-1 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301: 11661178.
  • Mukhopadhyay S, Howlett AC (2005). Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67: 20162024.
  • Nickerson M (1956). Receptor occupancy and tissue response. Nature 4535: 697698.
  • Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S et al. (2011). Distinct phosphorylation sites on the β-adrenergic receptor establish a barcode that encodes differential fucntions of β-arrestin. ScienceSignaling 4: 110.
  • Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW et al. (2009). Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of both ligands. Chem Biol 16: 452460.
  • Offermanns S, Wieland T, Homann D, Sandmann J, Bombien D, Spicher K et al. (1994). Transfected muscarinic acetylcholine receptors selectively couple to Gi-type proteins and Gq/11. Mol Pharmacol 45: 890898.
  • Okada T, Palczewski K (2001). Crystal structure of rhodopsin: implications for vision and beyond. Curr Opin Struct Biol 11: 420426.
  • Onaran HO, Costa T (1997). Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci 812: 98115.
  • Onaran HO, Scheer A, Cotecchia S, Costa T (2002). A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In: Kenakin TP , Angus JA (eds). The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology., Vol. 148. Springer: Heidelberg, pp. 217280.
  • Pei Y, Rogan SC, Yan F, Roth BL (2008). Engineered GPCRs as tools to modulate signal transduction. Physiology 23: 313321.
  • Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M et al. (2009). Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 50hysdroxytryptamine-4 receptors. Mol Pharmacol 75: 982990.
  • Perez DM, Karnick SS (2005). Multiple signaling states of G-protein coupled receptors. Pharmacol Rev 57: 147161.
  • Peters MF, Knappenberger K, Wilkins D, Sygowski LA, Lazor LA, Liu J et al. (2007). Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J Biomol Screen 12: 312319.
  • Prather PL, Loh HH, Lew PY (1994). Interaction of δ-opioid receptors with multiple G-proteins: a non-relationship between agonist potency to inhibit adenylate cyclase and to activate G-proteins. Mol Pharmacol 45: 9971003.
  • Prather PL, Martin NA, Breivogel CS, Childers SR (2000). Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G-protein α-subunits with different potencies. Mol Pharmacol 57: 10001010.
  • Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 14841495.
  • Raehal KM, Walker JKL, Bohn LM (2005). Morphine side effects in b-arrestin 2 knockout mice. J Pharmacol Exp Ther 314: 11951201.
  • Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, DeWire SM et al. (2011). Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80: 367377.
  • Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS et al. (2011). Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477: 549557.
  • Roerig SC, Loh HH, Law PY (1992). Identification of three separate guanine nucleotide- binding proteins that interact with the δ-opioid receptor in NG108-15 X glioma hybrid cells. Mol Pharmacol 41: 822. 831.
  • Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D et al. (1997). Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51: 357362.
  • Rosethorne EM, Charlton SJ (2011). Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol Pharmacol 79: 749757.
  • Roth BL, Chuang D-M (1987). Multiple mechanisms of serotonergic signal transduction. Life Sci 41: 10511064.
  • Samama P, Cotecchia S, Costa T, Lefkowitz RJ (1993). A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model. J Biol Chem 268: 46254636.
  • Sato M, Horinouchi T, Hutchinson DA, Evans BA, Evans RJ (2007). Ligand-directed signaling at the b3-adrenoceptor produced by 3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol 72: 13591368.
  • Scaramellini C, Leff P (2002). Theoretical implications of receptor coupling to multiple G proteins based on analysis of a three state model. Meth Enzymol 343: 1729.
  • Schröder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S et al. (2010). Deconvolution of complex G protein–coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28: 943949.
  • Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, Leahy P et al. (2006). p90 ribosomal S6 kinase exerts a tonic brake on G protein coupled receptor signaling. Proc Natl Acad Sci U S A 103: 47174722.
  • Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ (2008). Distinct conformational changes in β-arrestin report biased agonism at seven transmembrane receptors. Proc Natl Acad Sci U S A 105: 99889993.
  • Stephenson RP (1956). A modification of receptor theory. Br J Pharmacol 11: 379393.
  • Storjohann L, Holst B, Schwartz TW (2008). Molecular mechanism of Z2+ agonism in the extracellular domain of GPR39. FEBS Lett 582: 25832588.
  • Strachan RT, Dheffler DJ, Willard B, Kinter M, Kiselar JG, Roth BL (2009). Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling. J Biol Chem 284: 55575573.
  • Strachan RT, Sciaky N, Cronan MR, Kroeze WK, Roth BL (2010). Genetic deletion of p90 Ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine2A serotonin receptor functional selectivity. Mol Pharmacol 77: 327338.
  • Suratman S, Leach K, Sexton PM, Felder CC, Loiacono RE, Christopoulos A (2011). Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162: 16591670.
  • Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK (2004). Sequential Binding of Agonists to the 2 Adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem 279: 686691.
  • Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS et al. (2005). Porbing the β2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280: 2216522171.
  • Sykes DA, Dowling MR, Charlton SJ (2009). Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76: 543551.
  • Tilley DG (2011). G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 109: 217230.
  • Tobin AB (2008). G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 153: S167S176.
  • Tobin AB, Butcher AJ, Kong KC (2008). Location, location, location…site-specific GPCR phosphorylation offer a mechanism for cell-type-specific signaling. Trends Pharmacol Sci 29: 413420.
  • Tran JA, Chang A, Matsui M, Ehlert FJ (2009). Estimation of relative microscopic affinity constants of agonists for the active state of the receptor in functional studies on m2 and m3 muscarinic receptors. Mol Pharmacol 75: 381396.
  • Trankle C, Weyand A, Schroter A, Mohr K (1999). Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine (m2) receptors. Mol Pharmacol 56: 962965.
  • Tschammer N, Bollinger S, Kenakin T, Gmeiner P (2011). Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor. Mol Pharmacol 79: 575585.
  • Tutor A, Penela P, Mayor F (2007). Anti-β1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 76: 5160.
  • Valant C, Felder CC, Sexton PM, Christopoulos A (2012). Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effect. Mol Pharmacol 81: 4152.
  • Varga EV, Navratilova E, Stropova D, Jambrosic J, Roeske WR, Yamamura HI (2004). Agonist-specific regulation of the d-opioid receptor. Life Sci 76: 599612.
  • Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ (2005). Molecular basis of inverse agonism in a G-protein coupled receptor. Nat Chem Biol 1: 2528.
  • Vilardaga JP, Bunemann M, Krasel C, Castro M, Lohse MJ (2003). Measurement of the millisecond activation switch of G-protein-coupled receptors in living cells. Nat Biotechnol 21: 807812.
  • Violin JD, Lefkowitz RJ (2007). β-Arrestin biased ligands at seven transmembrane receptors. Trends Pharmacol Sci 28: 416422.
  • Violin JD, deWire SM, Yamashita D, Rominger DH, Nguyen L, Sciller K et al. (2010). Selectively engaging b-arrestins at the AT1R reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335: 572579.
  • Walters RW, Shukla A, Kovacs JJ, Violin JD, DeWire SM, Lam CM et al. (2009). β-arrestin 1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 119: 13121321.
  • Ward JS, Merrit L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD et al. (1995). Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazacycles. J Med Chem 38: 34693481.
  • Watson C, Chen G, Irving PE, Way J, Chen W-J, Kenakin TP (2000). The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58: 12301238.
  • Watson C, Jenkinson S, Kazmierski W, Kenakin TP (2005). The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 67: 12681282.
  • Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996a). The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 178: 151167.
  • Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996b). The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J Theor Biol 178: 169182.
  • Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996c). The cubic ternary complex receptor-occupancy model. III. Resurrecting Efficacy. J Theoret Biol 181: 381397.
  • Wise A, Sheehan M, Rees S, Lee M, Milligan G (1999). Comparative analysis of the efficacy of A1 adenosine receptor activation of Gi/0α G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor Gi/oα fusion proteins. Biochemistry 38: 22722278.
  • Woodward C (1993). Is the slow-exchange core the protein folding core? Trends Biochem Sci 18: 359360.
  • Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villen J et al. (2010). Global phosphorylation analysis of β-arrestin mediated signaling downstream of a seven transmembrane recetor (7TMR). Proc Natl Acad Sci U S A 107: 1529915304.
  • Yan F, Mosier PD, Westkaemper RB, Roth BL (2008). Gα-subunits differentially alter the conformation and agonist affinity of k-opioid receptors. Biochem 47: 15671578.
  • Zhou Y-Y, Cheng H, Song L-S, Wang D, Lakatta EG, Xiao RP (1999). Spontaneous β2-adrenergic signaling fails to modulate L-type nCa2+ current in mouse ventricular myocytes. Mol Pharmacol 56: 485493.
  • Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ (2009). Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A 106: 96499654.
  • Zurn A, Zabel U, Vilardaga JP, Schindlein H, Lohse MJ, Hoffmann C (2009). Fluorescence resonance energy transfer analysis of α2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 75: 534541.